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use#LAAThe knowns and unknowns in the biology and 
treatment of chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) is a low-grade B-
cell  malignancy,  characterized  by  the  accumulation  of 
mature  CD5+/CD19+/CD23+  lymphocytes  with  weak 
surface expression of a monoclonal immunoglobulin (Ig) 
[1] in the peripheral blood, bone marrow, lymph nodes 
and spleen. It is diagnosed either incidentally (with an 
abnormally high white blood cell count) in asymptomatic 
patients, or due to symptoms that result from cytopenias, 
adenopathy or constitutional symptoms, as outlined by 
the 2008 International Workshop on CLL [2]. CLL is part 
of  a  spectrum  of  pathological  conditions  involving 
clonally proliferating B cells. It is thought to be preceded 
by  monoclonal  B-cell  lymphocytosis  (MBL),  a  state  in 
which a smaller size B-cell clone is present, typically in 
the  absence  of  symptoms  [3].  At  the  other  end  of  the 
spectrum, CLL may transform into a higher-grade malig-
nancy, a process termed Richter’s transformation, which 
is often associated with a dismal clinical outcome [4].
CLL  possesses  several  features  that  place  it  at  the 
forefront  of  cancer  genetic  research.  First,  it  has  high 
relevance as the most common leukemia in adults [5]. 
Second, the ability to easily procure primary tumor cells 
from  the  bloodstream  facilitates  the  application  of 
cutting-edge genetic methodologies. Th   ese technologies 
have been used to defi  ne the underlying biology of CLL 
(for  instance,  elucidating  the  cell  of  origin  of  this 
lymphoid malignancy [6]), as well as to explore clinical 
questions (such as how to predict clinical outcome in a 
highly  variable  disease  on  the  basis  of  molecular  indi-
cators  [7]).  Th   ese  investigations  have  yielded  striking 
insights, including the fi  rst identifi  cation of a causative 
somatic microRNA alteration in cancer [8], as well as one 
of the fi  rst eff  ective molecular prognostic schemes [9].
In  parallel,  there  has  been  marked  progress  in  the 
development of therapeutic options in CLL (extensively 
reviewed  elsewhere  [10-12]).  While  the  general  thera-
peutic paradigm in CLL remains based on the ‘watch and 
wait’ approach (that is, treatment is initiated only when 
symptoms occur) [13], clinicians now have an extensive 
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Chronic lymphocytic leukemia (CLL) has been 
consistently at the forefront of genetic research owing 
to its prevalence and the accessibility of sample 
material. Recently, genome-wide technologies 
have been intensively applied to CLL genetics, with 
remarkable progress. Single nucleotide polymorphism 
arrays have identifi  ed recurring chromosomal 
aberrations, thereby focusing functional studies on 
discrete genomic lesions and leading to the fi  rst 
implication of somatic microRNA disruption in cancer. 
Next-generation sequencing (NGS) has further 
transformed our understanding of CLL by identifying 
novel recurrently mutated putative drivers, including 
the unexpected discovery of somatic mutations 
aff  ecting spliceosome function. NGS has further 
enabled in-depth examination of the transcriptional 
and epigenetic changes in CLL that accompany 
genetic lesions, and has shed light on how diff  erent 
driver events appear at diff  erent stages of disease 
progression and clonally evolve with relapsed disease. 
In addition to providing important insights into disease 
biology, these discoveries have signifi  cant translational 
potential. They enhance prognosis by highlighting 
specifi  c lesions associated with poor clinical outcomes 
(for example, driver events such as mutations in the 
splicing factor subunit gene SF3B1) or with increased 
clonal heterogeneity (for example, the presence of 
subclonal driver mutations). Here, we review new 
genomic discoveries in CLL and discuss their possible 
implications in the era of precision medicine.
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example, combination chemo-immunotherapy with flu-
dara  bine, cyclophosphamide and rituximab has yielded 
excellent long-term results [14]. Additionally, immuno-
therapy-based  therapeutics  such  as  alemtuzumab  [15] 
and  allogeneic  stem-cell  transplantation  [16,17]  have 
been demonstrated to provide effective disease control in 
treatment-refractory  or  high-risk  patients.  Importantly, 
as CLL often affects elderly individuals, more tolerable 
therapeutic  approaches  have  been  successfully  applied, 
such as lenalidomide [18] and bendamustine-based regi-
mens [19]. Most recently, therapies targeting the B-cell-
receptor  signaling  pathway,  such  as  ibrutinib,  have 
generated  excitement  as  they  have  shown  promising 
efficacy and tolerability in phase II clinical trials [20].
Despite the expansion of therapeutic options for CLL 
patients,  which  has  improved  patient  survival,  CLL 
remains  largely  incurable,  and  its  course  is  difficult  to 
predict. Furthermore, guidance about appropriate treat-
ment  selection  on  the  basis  of  individual  genetic  and 
molecular  abnormalities  remains  limited  [21].  A  full 
characterization  of  the  CLL  genomic  landscape  would 
enable several questions to be addressed. Can we accu-
rately predict the course of the disease? Can we predict 
which patients will respond to which therapies? And can 
we use genomic information to target the therapy to the 
underlying  genetic  or  other  alterations?  Over  the  past 
two  years,  genomic  approaches  have  been  intensively 
applied  for  studying  this  disease  and  have  aided  us  in 
answering these important questions (Figure 1). Here, we 
review the main findings of these investigations as well as 
their  possible  biological  and  clinical  implications, 
focusing on key findings obtained by genomic techno-
logies,  such  as  the  expanded  compendium  of  somatic 
gene  alterations  and  the  characterization  of  clonal 
evolution and of the epigenetic landscape of CLL.
Somatic copy number alterations
The study of somatic copy number alterations (sCNAs), 
which are somatically acquired alterations of a genome 
that  result  in  the  cell  having  an  abnormal  number  of 
copies of one or more sections of DNA, has revealed a 
high degree of molecular heterogeneity in CLL (reviewed 
extensively  elsewhere  [6,7,22]).  Briefly,  unlike  other 
lymphoid tumors such as follicular lymphoma or diffuse 
large  B-cell  lymphoma,  CLL  is  not  characterized  by  a 
common translocation involving the Ig loci, but instead 
by specific recurrent sCNAs (such as chromosome 11q 
deletions (del(11q)), trisomy 12, del(13q) and del(17p)) 
that  have  been  observed  using  comparative  genome 
hybridi  zation [23] and single nucleotide polymorphism 
(SNP)-array-based  investigations  [24]  (Table  1).  Con-
sider  ing the near-diploid genome of CLL (only a small 
number of sCNAs are typically observed in CLL), these 
are  probably  causative  events,  as  the  finding  of  highly 
recurrent events against a backdrop of a low background 
sCNA rate testifies to significant selection and hence to a 
significant  fitness  advantage  afforded  to  CLL  cells  by 
these lesions. Furthermore, they affect clinical outcome 
[9]: del(13q) is associated with a good prognosis whereas 
del(11q) and del(17p) are associated with a poor prog-
nosis with present-day chemo-immunotherapy approaches. 
Lower frequency lesions have also been identified involv-
ing the MYC locus [25], the short arm of chromosome 8 
[23], and lesions probably affecting PIK3CA, NFKB2 and 
MGA [26,27]. Allele-specific copy number quantification 
with SNP arrays has also enabled the discovery of fre-
quent copy-neutral loss of heterozygosity in CLL, often 
resulting  in  biallelic  hits  (mutations  or  epigenetic 
alterations) in key CLL-related loci, and therefore poten-
tially altering function [24]. For example, duplication of 
the  allele  containing  the  small  del(13q)  event  may  be 
concurrent with the loss of the sister normal allele.
Figure 1. In recent years, CLL has been investigated through the 
use of several novel genomic technologies. CLL is a disease of 
mature B cells that is typically present in high abundance in blood; a 
typical peripheral blood smear is shown in the top panel. The typical 
source material used for these studies is primary peripheral blood 
CLL samples. Four main genomic approaches have been applied 
to this disease, including whole-exome/genome DNA sequencing, 
SNP arrays for copy number measurement, RNA sequencing and 
analyses of DNA methylation. These studies have added a substantial 
amount of information regarding the biology of CLL. CLL, chronic 
lymphocytic leukemia; LOH, loss of heterozygosity; SNP, single 
nucleotide polymorphism.
• Unbiased discovery of putative drivers (for example, SF3B1)
• Uncovering mutational mechanisms (for example, chromothripsis) 
• Tracking clonal evolution and its impact on clinical outcome
 
• Gene expression profiles to define the normal cellular counterpart
  and prognostic groups
• Systems analysis of cellular networks to reveal converging
  cellular disruption patterns associated with disease progression
• Detection of splicing variations
RNA sequencing and expression arrays
Whole-genome and -exome sequencing 
• Unbiased identification of recurrent chromosomal alterations
• Detection of copy-neutral LOH (promotes silencing of tumor 
suppressors) 
SNP arrays
• Detection of methylation changes at single base-pair resolution
• Delineation of the normal cellular counterpart of CLL 
• Identification of novel prognostic groups in CLL 
Methylation conversion sequencing
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across many CLL patient samples, and thus defining the 
size of minimally affected lesions, these methodologies 
have  contributed  to  a  mechanistic  understanding  of 
causa  tive  lesions  in  CLL.  For  instance,  the  minimal 
deleted region in del(13q14) focused functional investi-
gation  onto  a  small  number  of  genetic  elements,  and 
ultimately led to the discovery that the microRNAs miR-
15a and miR-16-1, encoded by an intron of DLEU2, have 
a causative role in CLL [8], perhaps through the release of 
the anti-apoptotic BCL2 protein from microRNA-medi-
ated  downregulation  [28].  More  recently,  the  case  for 
miR-15a/16-1  deletion  having  a  causative  role  in  CLL 
was strengthened with the generation of a CLL mouse 
model based on knockout of this locus [29]. Significant 
variation in the size of the deleted region (from approxi-
mately 300 kilobases to more than 50 megabases) pro-
vides  clues  to  additional  contributing  genetic  compo-
nents [30]. For example, adjacent hits within large mono-
allelic  deletions  (affecting,  for  example,  the  RB1  gene) 
may have an important contributory role compared with 
a more isolated effect of the disruption of the microRNA 
cluster in the shorter biallelic deletions. While del(11q) 
and del(17p) impact the cellular network primarily due to 
the deletion of known tumor suppressor genes ATM and 
TP53, respectively, the mechanism by which trisomy 12 
contributes to lymphoproliferation remains unknown [7]. 
This is due in part to the large size of the affected lesion 
(an entire chromosome), which limits the ability to focus 
investigations on a smaller number of genes; application 
of  large  RNA  interference  screen-based  approaches, 
however, may reveal candidate genes.
Clinical application of this information yielded one of 
the earliest molecular classification schemata in cancer, 
predicting the course of disease based on the identity of 
the  sCNA  [9].  This  is  of  particular  importance  in  a 
disease  like  CLL  where  the  clinical  heterogeneity  is 
enormous, with some patients remaining stable without 
treatment for years or even decades, while others follow a 
fulminant  and  treatment-refractory  course.  Higher 
genomic complexity - the presence of a high number of 
sCNAs - has also been associated with worse outcome, 
including shorter time to first therapy and lower overall 
survival rate [31,32]. Nevertheless, in contrast to other 
tumors, CLL has a relative paucity of sCNAs [26]. This 
observation has led to the suggestion that somatic single 
nucleotide  variants  (sSNVs)  and  indels  could  play  an 
important role in the pathogenesis of CLL, paving the 
way  for  the  application  of  next-generation  sequencing 
(NGS) technologies to this disease.
The genomic landscape of CLL probed with 
next‑generation sequencing
NGS studies of the CLL genome [33,34] have effectively 
elucidated the level of genomic complexity in CLL, and 
have  revealed  that  the  average  number  of  non-silent 
mutations  (that  is,  mutations  that  alter  the  protein 
sequence) is 10 to 20 per each sequenced CLL sample 
(out  of  approximately  1,000  somatic  mutations  per 
sample detected genome-wide). This is at least an order 
of magnitude lower than the number of lesions detected 
in  the  coding  genomes  of  common  epithelial  cancers, 
such  as  lung  cancer  or  melanoma  [35].  Even  among 
hemato  logic  malignancies,  the  genomic  complexity  of 
Table 1. Recurrent sCNAs in peripheral blood primary CLL samples
  Frequency    Frequency  More common  Prognostic 
sCNA  in CLL (%)  Likely target  in MBL (%)  IGHV status  significance
del(13q14)  57 to 61 [26,27]  miR-15a/16, encoded in an intron of DLEU2 [8].  48 [112]  None  Good [9]
    Its deletion leads to the release of BCL2 from
    microRNA-mediated down-regulation [28]
del(11q22.3)  6 to 27 [26,27]  ATM, BIRC3  Rare  Unmutated  Poor [9]
Trisomy 12  11 to 12 [26,27]  Unknown [7]  20 [112]  None  None [9]
del(17p)  6 to 8 [26,27]  TP53  Rare  Unmutated  Poor [9]
amp(2p)  7 [27]  XPO1, BCL11A  Unknown  Unmutated  None [27]
amp(8q24.21)  5 [26,27]  MYC  Unknown  Unmutated  Poor [26,27]
del(15q15.1)  4 [27]  MGA  Unknown  Unknown  None [27]
del(10)(q24)  2 [27]  NFKB2  Unknown  Unknown  Unknown
del(18p)  3 [27]  Unknown  Unknown  Unmutated [27]  Unknown
del(6q)  7 [27]  Unknown  Unknown  Unknown  Unknown
amp(3q26.32)  6 [26]  PIK3CA  Unknown  Unknown  Poor [26]
del(8p)  5 [23,26]  Unknown  Unknown  Unknown  Poor [26]
amp, amplification; sCNA, somatic copy number alterations; MBL, monoclonal B-cell lymphocytosis.
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[36]. The overwhelming majority of sSNVs involve C>T 
transitions at CpG sites, with some differences in muta-
tion  patterns  between  CLL  with  mutations  in  the  Ig 
heavy variable region (IGHV-mutated) and CLL lacking 
IGHV  mutations  (IGHV-unmutated),  suggestive  of  the 
involvement  of  aberrant  somatic  hypermutation  with 
error-prone  repair  [33].  Importantly,  the  number  of 
mutations in CLL samples from patients who received 
chemo-immunotherapy  before  sampling  is  not  signifi-
cantly increased [34]. These results suggest that, unlike 
several  other  cancers  such  as  glioblastoma  [37],  CLL 
treat  ment does not substantially contribute to increased 
mutagenesis.
NGS has also uncovered an unusual form of genomic 
complexity in CLL, termed chromothripsis, which results 
from a massive genomic rearrangement event within a 
single  region  through  an  as  yet  unknown  underlying 
mechanism [38]. Overall, chromothripsis was detected at 
a  substantial  frequency  in  CLL  (approximately  2%) 
through  inference  from  SNP-array  data,  and  was  seen 
almost exclusively in CLL with IGHV-unmutated status 
and with mutated TP53. This observation suggests that 
although genome integrity is largely preserved in CLL (as 
demonstrated by its typically near-diploid genome), cata-
strophic  rearrangements  can  be  tolerated  and  selected 
within a permissive genetic context. Perhaps unsurpris-
ingly, chromothripsis has been associated with a worse 
prognosis [27].
Beyond  the  characterization  of  the  mutational  land-
scape in CLL, NGS has also been used to study, in an 
unbiased fashion, recurrent genetic alterations in CLL. 
Putative driver mutations, which are genetic lesions that 
are likely to confer a significant fitness advantage, have 
been identified (Tables 2 and 3). The first studies reported 
whole-genome [33] or whole-exome [39] sequencing of a 
handful of CLL samples, followed by targeted sequencing 
of coding mutations detected in these samples in larger 
validation cohorts. This approach uncovered several im-
por  tant putative drivers, including MYD88 and NOTCH1 
mutations. An alternative approach using a larger initial 
cohort probed with whole-exome sequencing has enabled 
the  discovery  of  a  larger  number  of  putative  drivers 
[34,40].  Collectively,  these  studies  have  demonstrated 
wide  heterogeneity  in  the  genetic  lesions  driving  CLL 
transformation and progression, characterized by ‘moun-
tains’ (that is, highly recurrent genes such as TP53) and 
‘hills’ (infrequent but still statistically significant recur-
rent genes such as XPO1), as seen in other sequencing 
efforts [41].
One of the earliest CLL drivers identified through NGS 
was  NOTCH1  [33,34,39].  NOTCH1  encodes  a  ligand-
activated  transcription  factor  that  regulates  several 
down  stream pathways important for the control of cell 
growth.  One  recurrent  mutation  (c.7544_7545fsdel) 
accounts for approximately 80% of all NOTCH1 muta-
tions and generates a premature stop codon in the PEST 
domain (a peptide rich in proline (P), glutamic acid (E), 
serine (S) and threonine (T), thought to act as a signal for 
protein  degradation  [42]),  which  normally  limits  the 
inten  sity and duration of NOTCH1 signaling [39]. Dis-
rup  tion  of  the  PEST  domain  results  in  impaired 
NOTCH1 degradation, as it interferes with phosphory-
lation  of  the  PEST  domain  of  the  receptor  and  its 
proteasomal degradation through the FBXW7-SCF ubi-
quitin ligase complex [43]. This in turn results in accu-
mulation of an active NOTCH1 isoform, which is asso-
ciated  with  a  distinct  transcriptional  signature  [33].  In 
CLL, the frequency of NOTCH1 mutations is above 10%, 
and tends to occur in CLLs without IGHV mutation and 
with trisomy 12 [44], although it is important to note that 
the  latter  association  was  not  found  in  another  recent 
study  [45].  In  some  studies,  the  presence  of  NOTCH1 
mutations provided independent prognostic information 
and identified a group of patients with intermediate-risk 
disease [46] and those in whom CLL was more likely to 
transform into high-grade lymphoma [47]. However, the 
effect size may not be as prominent as other CLL prog-
nostic  indicators,  as  further  studies  failed  to  show  an 
independent prognostic value for the presence of these 
mutations [47,48].
Another commonly mutated gene is MYD88, a critical 
adaptor molecule of the Toll-like receptor (TLR) complex 
[33,34], seen in 3 to 8% of CLL cases. After TLR stimu-
lation, MYD88 is recruited to the receptor as a homo-
dimer  and  forms  a  complex  with  IRAK4,  leading  to 
activation of IRAK1 and IRAK2. This then leads to the 
downstream  activation  of  TRAF6  and  ultimately  to 
phosphorylation of IκBα and activation of the central B-
cell transcription factor, nuclear factor (NF)-κB [49,50]. 
The recurrent MYD88 mutation in CLL (L265P) imposes 
constitutive MYD88-IRAK signaling even in the absence 
of ligand-receptor binding, and thereby provides con  sti-
tutive NF-κB activity. Of note, MYD88 L265P mutations 
have been found exclusively in CLL with mutated IGHV. 
Exactly the same mutation has been identified in other 
malignancies of mature B cells such as diffuse large B-cell 
lymphoma [51], central nervous system lymphoma [52] 
and  Waldenström’s  macroglobulinemia  [53].  Further-
more,  this  aberration  is  potentially  amenable  to  thera-
peutic targeting through direct inhibition of the MYD88-
IRAK complex, through proteasomal inhibition [54] or 
even through the inhibition of Bruton’s tyrosine kinase 
(BTK) [55].
Putative drivers can be further categorized based on 
the cellular pathways they involve. Recurrently mutated 
genes  in  CLL  can  be  grouped  into  seven  core  cellular 
networks, in which the genes play well-established roles. 
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cycle control, Notch signaling, inflammatory pathways, 
Wnt signaling, RNA splicing and processing (found to be 
present  in  close  to  one-third  of  CLLs  [56]),  B-cell 
receptor signaling and chromatin modification. Pathway 
analysis may also be beneficial to detect commonly dis-
rupted pathways that may be of high biological relevance 
but that do not contain a single highly recurrent gene, 
and may be missed by gene-centric analytic approaches. 
One such example is disruption of the Wnt pathway [34], 
a key player in CLL biology [57,58].
Although  the  unbiased  approach  of  whole-exome 
sequencing of large cohorts is highly effective at detecting 
putative drivers, it may still miss important drivers, either 
owing to lack of power to detect lower frequency events 
or  to  the  patient  characteristics  of  the  investigated 
cohort. A striking example of such drivers is the case of 
BIRC3-inactivating  mutations,  which  have  not  been 
detected in most of the large sequencing efforts. Targeted 
sequencing of the BIRC3 coding sequence in CLL showed 
that  BIRC3  inactivation  is  particularly  common  in  flu-
darabine-refractory  patients  (24%)  [59].  BIRC3,  along 
with TRAF2 and TRAF3, cooperates in negatively regu-
lat  ing  MAP3K14,  an  activator  of  the  non-canonical 
pathway  of  NF-κB  signaling  [60],  and  therefore  BIRC3 
muta  tions  result  in  constitutive  NF-κB  activation  [59]. 
Thus, BIRC3 mutations join SF3B1 (described in the next 
section), NOTCH1 and TP53 as mutations that contri-
bute  to  chemo-refractoriness  [61].  This  example  high-
lights  the  need  to  include  specific  patient  groups  in 
sequencing efforts. Furthermore, it supports the idea that 
driver  landscapes  of  similar  types  of  malignancies  can 
guide driver identification, as the study of BIRC3 in CLL 
was prompted by its discovery in splenic marginal zone 
lymphoma [62].
Spliceosome mutations are important driver 
events in CLL
One  of  the  most  unexpected  and  important  findings 
arising from an unbiased NGS discovery approach was 
the identification of SF3B1 as one of the most recurrently 
mutated genes in CLL [63]. SF3B1 is a central component 
of the U2 spliceosome, which orchestrates the excision of 
introns  from  pre-mRNA  to  form  mature  mRNA  [64]. 
Strikingly, SF3B1 mutations are found in 10 to 14% of 
CLLs, particularly in CLL without IGHV mutation [34,40]. 
This  discovery  coincided  with  the  report  of  fre  quent 
somatic disruptions of the splicing machinery in myelo-
dysplastic syndrome [65], thereby marking a new im  por-
tant path to oncogenesis in hematological malignancies 
Table 2. High‑frequency recurrently mutated genes in CLL
        Richter’s* or  Gene 
  Frequency  Likely gene  Frequency  chemo-refractory  mutation  More common  Prognostic 
Gene  in CLL (%)  function  in MBL (%)  cases  hotspots  IGHV status  significance
TP53  7.5 to 13 [34,39,75]  Apoptosis, DNA repair  Rare [76]  Yes [46]  Inactivating   Unmutated  Poor [46]
          mutations
SF3B1  10 to 14 [34,40,  Splicing factor  Rare [76]  Yes [46]  K700E  Unmutated  Poor [34,40]
  75,113]
NOTCH1  10 to 17 [33,34,39,  Developmental  Rare [76]  Yes [39]  P2515Rfs*4  Unmutated  Poor [46]
  40,75,113]  processes
MYD88  3 to 8 [33,34,75]  TLR adaptor  Unknown  Unknown  L265P  Mutated  None
ATM  8 to 15 [34,75,114]  DNA repair  Unknown  Unknown  Inactivating   Unmutated  Poor [114]
          mutations
BIRC3  4 [39,59]  NF-κB pathway  Absent [59]  Yes [59]  Inactivating   Unmutated  Poor [46]
    inhibitor      mutations
*Richter’s transformation, in which CLL transforms to a higher-grade malignancy.
Table 3. Low‑frequency recurrently mutated genes in CLL
Gene  Frequency (%)  Likely gene function
XPO1  2 to 4 [33,75]  Nuclear export
CHD2  4 to 5 [40,75]  Chromatin modification
POT1  3 to 5 [40,75]  Telomere maintenance
HIST1H1E  3 [75]  Histone protein
NRAS  3 [75]  Cell growth
BCOR  3 [75]  Apoptosis regulation
ZMYM3  3 [34,75]  Chromatin modification
RIPK1  3 [75]  Inflammatory pathway
SAMHD1  3 [75]  Innate immune response
KRAS  2 [75]  Cell growth
MED12  2 [75]  Gene transcription
ITPKB  2 [75]  B-cell signaling
DDX3X  2 [34,75]  RNA helicase
EGR2  1 [75]  Transcription factor
FBXW7  3 [34,75]  Ubiquitination
KLHL6  2 [33]  B-cell receptor signaling
MAPK1  3 [34]  MAP kinase
LRP1B  5 [40]  LDL receptor family
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identification of a recurrently mutated gene in both un-
mutated IGHV CLL and myeloid malignancies may hint 
at a role of dysregulated hematopoietic stem/progenitor 
cells in some mature lymphoid malignancies [70].
The  pathogenic  role  of  SF3B1  mutations  is  not  only 
supported by its frequent occurrence in CLL, but also by 
the  fact  that  mutations  cluster  in  evolutionarily  con-
served  hotspots  within  its  carboxy-terminal  repeat 
HEAT domains, whose function remains unknown [34]. 
Figure 2. Affected genes in CLL discovered through genomic sequencing studies can be grouped into seven core cellular pathways. 
Genes recurrently mutated in CLL samples are shown in red ovals, while genes found to be mutated in isolated samples but which did not reach 
statistical significance are shown as pink ovals. Affected cellular elements include four signaling pathways with a known role in B-cell biology: 
inflammatory pathways, B-cell receptor signaling, Notch signaling, and Wnt signaling. Notch and Wnt signaling both provide important pro-survival 
input for CLL cells, allowing them to evade apoptosis [115-117]. In addition, they serve as an important bridge with the microenvironment, which 
is of particular importance in CLL, as manifested by relatively poor cell survival outside of the endogenous niche (for example, in in vitro or in vivo 
animal models) [118]. BCR signaling and inflammatory pathways may serve similar functions, and in addition may form optimal early targets for 
somatic mutations as they hijack physiologically active cellular pathways in relatively differentiated B cells [75,119]. In addition, three intranuclear 
processes are involved, including DNA repair, chromatic modification and RNA processing. Although the role of DNA repair disruptions has been 
extensively investigated, with multiple effects on pro-survival circuits, growth and genetic plasticity [120,121], the role of the other two intranuclear 
processes remains to be fully elucidated in CLL. IC, intracellular; C, cytoplasm.
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some complex that is incapable of performing the correct 
splicing steps. It has been reported that CLL cells with 
SF3B1 mutations show defective splicing activity, with a 
high  ratio  of  unspliced  to  spliced  BRD2  and  RIOK3 
mRNA, transcripts that have previously been shown to 
require SF3b spliceosome activity [34,73]. Elevated levels 
of truncated mRNA of the transcription factor FOXP1 
and additional proteins that are SF3b spliceosome targets 
have been reported in association with SF3B1 mutation 
[40]. The precise mechanistic aspects of SF3B1 mutation, 
however, are still under investigation. Of note, in addition 
to SF3B1 mutations, disruptions of other aspects of RNA 
processing have been observed in CLL, including recur-
rent mutations in DDX3X and XPO1 [34], highlighting 
the importance of RNA processing in CLL.
Patients with SF3B1-mutated CLL have a shorter time 
to treatment, a shorter time to disease progression and 
lower overall survival rates [34,40]. These mutations were 
also  found  in  higher  rates  in  patients  with  chemo-
refractory CLL [69]. Other data indicate that the SF3B1 
mutation may be a later event in CLL, as it was observed 
to be acquired in patients with relapsed disease [74], or 
that  it  expands  from  a  minor  subclone  to  become  the 
dominant  subclone  upon  relapse  [75].  Along  the  same 
lines, it has been suggested that it is rarely seen in MBL 
[76], a clonal condition that is thought to precede CLL, 
although  the  sample  size,  particularly  of  CLL  samples 
with  unmutated  IGHV,  may  have  been  too  small  to 
adequately  address  this  question.  SF3B1  mutations 
therefore  may  have  a  role  in  clonal  evolution  in  CLL, 
emerging later in the disease course, and in relapsed or 
refractory disease.
Clonal evolution drives CLL progression
One of the main challenges for cancer therapeutics is the 
plasticity  of  cancer  -  its  ability  to  adapt  both  to  host 
defenses and to treatment. A central component of this 
plasticity is clonal evolution fueled by the coexistence of 
multiple  subpopulations  within  the  tumor  [77].  These 
concepts  were  first  demonstrated  in  CLL  using  cyto-
genetic technologies [78] and more recently using SNP 
arrays,  which  have  also  shown  that  relapsed  disease  is 
genetically  altered  compared  with  disease  at  diagnosis 
[23,79,80].
With  the  advent  of  NGS,  clonal  evolution  has  been 
characterized at unprecedented resolution using whole-
genome sequencing of small cohorts of patients with a 
variety  of  cancers  [81-84].  In  CLL,  whole-genome  se-
quencing was performed to track clonal heterogeneity in 
three  CLL  patients  subjected  to  repeated  cycles  of 
therapy  [85].  Notably,  three  very  different  temporal 
patterns  of  repopulation  of  the  leukemic  cell  mass 
emerged after therapy, varying from a stable equilibrium 
between five subpopulations over the course of years in 
one patient, to marked shifts, in which one minor sub-
clone replaced the dominant clone entirely, in another. 
These  findings  suggest  the  existence  in  CLL  of  an 
intricate ‘ecology’ in which a complex interplay is present 
between  intrinsic  and  extrinsic/environmental  factors 
that control the balance between different subpopulations 
within the entire CLL population [86].
Recently, we investigated clonal evolution in CLL by 
using whole-exome sequencing [75]. The methodologies 
developed in this study enabled the analysis of a large 
cohort  of  samples  involving  149  patients,  including  18 
cases that were followed longitudinally. By studying the 
allelic fraction of each mutation, the proportion of the 
subpopulation that harbored it among the entire cancer-
cell  mass  was  inferred,  and  each  mutation  event  was 
classified as either clonal, meaning a mutation that affects 
all cancer cells (and corresponding to a founder mutation 
or  an  earlier  mutation  that  underwent  a  complete 
selective sweep that eliminated all other cancer cells not 
bearing this mutation), or subclonal, which affects a sub-
population of cancer cells (representing events acquired 
later in the disease course).
This framework enabled the inference of the temporal 
order of genetic driver events in CLL, with the identi-
fication of earlier (for example, MYD88 mutation) and 
later events (for example, TP53 mutation) in disease pro-
gression. We also tracked clonal evolution longitudinally 
in 18 patients [75], observing that patients who received 
therapy had a higher rate of clonal evolution, suggesting 
that  perhaps  chemotherapy  itself  can  hasten  the 
evolutionary  process.  Finally,  clonal  heterogeneity  was 
linked  to  adverse  clinical  outcome,  adding  a  further 
dimension  to  current  efforts  to  link  discrete  somatic 
muta  tions to outcome. These findings suggest that it is 
not  only  the  presence  or  absence  of  a  mutation  that 
should  be  considered  in  analyses  of  the  impact  of 
mutations on clinical outcome, but also the size of the 
subpopulation  a  mutation  affects.  This  finding  has 
important  clinical  implications  that  can  be  tested  in 
prospective clinical trials.
Beyond somatic genetic alterations: epigenetic 
changes in CLL
Cancer has traditionally been viewed as a disease driven 
by  the  accumulation  of  genetic  mutations  [87].  This 
paradigm has been increasingly modified as cumulative 
evidence has suggested that the disruption of epigenetic 
regulatory mechanisms has a critical role in neoplastic 
transformation [88,89]. In CLL, for example, epigenetic 
modifications  have  been  implicated  in  the  recurrent 
microRNA deregulation observed in miR-15a/16 and the 
related miR-29b [90]. Histone deacetylases were shown 
to be overexpressed in CLL, and mediate the epigenetic 
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activating chromatin modification H3K4me2.
Perhaps  the  best-studied  epigenetic  modification  in 
CLL has been direct DNA methylation, which occurs at 
the cytosine residue of the CpG dinucleotide in mam-
malian  genomes.  Patterns  of  DNA  methylation  can  be 
inherited across generations of somatic cells as they are 
stably maintained through somatic cell division. This type 
of  epigenetic  alteration  is  at  least  as  common  as 
mutational  events  in  the  development  of  cancer  [91]. 
Published  reports  of  epigenetic  gene  dysregulation  in 
CLL  include  hypomethylation  of  BCL2  [92]  and  TCL1 
[93],  as  well  as  silencing  of  DAPK1  through  promoter 
hypermethylation,  which  recapitulates  a  germline 
mutation found in a kindred of familial CLL [94].
More  recently,  genome-wide  platforms  have  been 
applied to the study of DNA methylation in CLL. DNA 
methylation  arrays  detect  representative  methylation 
sites  across  the  entire  genome  and  have  been  used  to 
identify  regions  with  differential  methylation  in  CLL 
samples with mutated or unmutated IGHV status [95]. 
Most of these differentially methylated regions have been 
reported to lie outside CpG islands, to remain stable over 
time  and  to  involve  multiple  genes  important  in  CLL 
biology, such as ZAP70, NOTCH1 and IBTK, as well as 
epigenetic  regulators  (such  as  DNMT3B)  and  NF-κB/
tumor necrosis factor (TNF) pathway genes [95]. Similar 
investigations were performed comparing CLL samples 
with high and low CD38 expression, and found variable 
methylation in the DLEU7 gene [96]. Finally, pervasive 
methylation changes have been observed across numer-
ous  microRNA  sites  in  CLL  samples  compared  with 
normal B cells, which were associated with large changes 
in expression of these microRNAs [97].
Bisulfite conversion coupled with NGS has also been 
used  to  delineate  DNA  methylation  across  the  entire 
genome at base-pair resolution [98]. Using this method, 
methylation  profiles  have  been  shown  to  vary  sub-
stantially between CLL with mutated versus unmutated 
IGHV  status  and  to  mirror  epigenetic  differences  seen 
between  naive  and  memory  B  cells.  The  methylation 
patterns  observed  in  the  study  allowed  the  authors  to 
identify, in addition to the mutated and unmutated IGHV 
subsets,  a  third  subset  of  CLL  samples  with  distinct 
clinical behavior (an intermediate prognosis group, with 
a better prognosis than patients with IGHV-unmutated 
CLL  and  a  worse  prognosis  than  those  with  IGHV 
mutations), and an intermediate level of IGHV somatic 
hypermutation. Another method using bisulfite conver-
sion  focuses  on  a  representative  sample  of  CpG  sites 
termed  reduced  representation  bisulfite  sequencing 
(RRBS). This method has been found to be highly infor-
ma  tive,  and  is  less  costly  than  whole-genome  bisulfite 
conversion [99]. The application of RRBS to CLL [100] 
has  shown  that  differentially  methylated  regions  are 
enriched for transcription factors, including the homeo-
box family of proteins. Furthermore, DNA methylation 
serves  to  enhance  particular  critical  pathways  in  CLL, 
such as Wnt signaling, by the simultaneous hypermethy-
lation  of  pathway  antagonists  (for  example,  DKK)  and 
hypomethylation  of  Wnt  ligands  and  transcription 
factors  (for  example,  TCF7),  with  the  net  result  of 
decreased antagonist transcription and increased agonist 
transcription,  respectively.  Collectively,  these  studies 
have  shown  that  DNA  methylation  probably  plays  a 
significant role in CLL biology.
Profiling the transcriptional landscape of CLL to 
understand the impact of genetic and epigenetic 
alterations on the cellular network
The various genetic and epigenetic alterations described 
earlier can affect the cellular network and lead to system-
wide transcriptional changes. Studying the transcriptome 
enables an understanding of how mutations alter cellular 
behavior, and this should give a better idea of the ultimate 
phenotype.  Expression  arrays  have  been  used  to  study 
CLL for many years in an effort to define subtypes related 
to  clinical  outcomes  (reviewed  extensively  elsewhere 
[101-103]). These methodologies have also been used to 
classify different subtypes (for example, IGHV-mutated 
versus IGHV-unmutated) as well as to try and identify 
the  normal  cellular  counterpart  of  CLL  (that  is,  the 
closest normal B-cell phenotype that may serve as a cell 
of origin for CLL) [104].
A  systems-level  examination  of  the  transcriptional 
landscape of CLL has the potential to reveal subsets of 
patients  with  disparate  risks  for  CLL  progression.  By 
studying individual pathway disruptions, these pathways 
were  shown  to  converge  as  patients  progressed  before 
treatment and to assume similar transcriptional profiles 
closer  to  the  point  at  which  they  required  treatment 
[105].  Thus,  the  transcriptional  profile  of  CLL  can  be 
reduced from a daunting number of individual genes to a 
handful of meaningful pathway annotations with impor-
tant biological and clinical implications.
High-throughput  RNA  sequencing  has  enabled  the 
harnessing  of  NGS  technology  for  the  study  of  trans-
criptional  profiles.  A  pilot  study  compared  RNA-
sequencing data from a small number of samples with 
mutated  versus  unmutated  IGHV,  the  most  well-
established prog  nostic factor in CLL [106]. In addition to 
identifying 156 differentially expressed genes, the study 
identified a large number of differentially expressed non-
coding RNAs as well as marked changes in splice variants 
between  the  two  prognostic  groups.  Thus,  this 
methodology is capable of providing a wealth of infor-
mation  in  comparison  with  microarray-based  gene 
expression profiling, with the potential to demonstrate 
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cellular network level.
Conclusions and future directions
The intensive application of NGS to the study of CLL has 
yielded remarkable insights over a short period of time, 
and  it  is  likely  that  the  exponential  growth  in  our 
understanding of this disease will continue in the coming 
years. The use of these novel technologies has identified 
expected (for example, TP53 and ATM mutations) and 
unexpected CLL drivers (for example, SF3B1), and has 
opened  new  avenues  of  research,  such  as  the  study  of 
splicing abnormalities (Figure 2). NGS has also revealed 
the tremendous degree of genetic heterogeneity in CLL, 
both  among  patients  and  within  individual  leukemias 
over time.
Delineating the inter-patient genetic heterogeneity of 
CLL has high translational potential. First, novel genetic 
abnormalities  such  as  NOTCH1,  SF3B1  and  BIRC3 
mutations carry prognostic significance, and will probably 
be used in the future to predict the highly variable clinical 
course of CLL, beyond the established predictive factors 
such  as  IGHV  mutation  status  and  cytogenetic  abnor-
malities  [46].  Second,  these  lesions  may  also  be  infor-
mative regarding treatment stratification - similar to the 
use  of  TP53  disruption  today,  which  is  known  to  be 
associated  with  chemo-refractory  disease  [2].  Finally, 
some of the genetic lesions identified by NGS represent 
attractive candidates for targeted therapy. NOTCH1, for 
example, is already being targeted by some drugs under 
development [107]. The promising results obtained with 
inhibitors of BCR signaling (that is, the BTK inhibitor 
ibrutinib and the PI3K-δ inhibitor GS-1101 [20]) suggest 
that future research should also focus on how these drugs 
affect CLL cells with different driver lesions.
The emerging understanding of intra-tumoral genetic 
heterogeneity in CLL may also eventually have a clinical 
impact. Studying clonal evolution in relation to therapy 
could help us to refine our understanding of resistance 
mechanisms  and  repopulation  kinetics.  For  example, 
studying  the  genomes  of  relapsed  CLL  compared  with 
pre-treatment  CLL  patients  could  be  informative  with 
respect to specific lesions or mutations that are selected 
in vivo in the setting of therapeutic bottlenecks. Collect-
ing multiple longitudinal samples throughout the disease 
and treatment process could highlight the comparative 
kinetics  of  different  subpopulations,  enhancing  our 
under  standing  of  the  evolutionary  process.  It  will  also 
enable  us  to  gain  an  understanding  of  the  impact  of 
targeting early clonal lesions compared with late aggres-
sive  subclonal  drivers  on  therapeutic  outcome.  Finally, 
the  suggestion  that  therapy  itself  can  accelerate  clonal 
evolution could influence the current paradigm of gene-
specific  discovery,  by  challenging  us  to  conceive 
therapeutic strategies to directly address and anticipate 
clonal evolution, which has been demonstrated to affect 
clinical outcome [75].
Future directions for NGS-based studies will probably 
also include studying the entire continuum of CLL, from 
MBL to Richter’s transformation [39,61]. Studying MBL 
may  be  particularly  informative  regarding  the  nascent 
stages of CLL and the critical genetic steps required for 
transformation to CLL. In addition, focusing on distinct 
groups of patients, such as those with poor clinical out-
come (rapid progression and poor treatment res  ponse), 
would assist in defining the genetic elements that contri-
bute to disease heterogeneity. Some of these have already 
been  identified,  such  as  the  long-established  role  of 
mutations in TP53 and ATM, as well as the more recent 
identification  of  the  poor  prognostic  significance  of 
SF3B1  and  BIRC3 mutations. However,  it  is  likely  that 
other somatic events or specific mutation combinations 
can  affect  clinical  phenotype,  and  a  comprehensive 
mapping of these elements will improve prognostication. 
Pathway  analysis,  as  portrayed  in  Figure  2,  may  also 
unravel how disruption of different parts of the cellular 
machinery can translate into altered clinical outcome.
Moreover, these technologies are likely to be applied to 
studying inherited predisposition for CLL [108,109], as 
this disease has a high incidence of familial cases. This 
area  of  investigation  might  provide  important  clues  to 
the interaction between existing germline mutations and 
acquired  somatic  mutagenesis.  Finally,  probing  the 
epigenetic profile of CLL is currently in its nascent stages 
and will likely lead to a better understanding of genome-
wide levels of epigenetic modifications, as well as how 
different populations within the cancer-cell mass differ in 
their epigenetic profiles and how this affects functional 
diversity. For example, these epigenetic differences might 
lead  to  variations  in  proliferative  capacity,  pluripotent 
potential [110] or ability to resist therapy [111].
Ultimately,  a  comprehensive  understanding  of  the 
genetic basis of CLL will assist in stratifying patients and 
matching treatments with genetic lesions, with a goal of 
developing targeted therapies to improve CLL manage-
ment.  The  wealth  of  emerging  genetic  data  has  great 
potential to provide new paths for improved treatment 
options for this disease, and will require focused trans-
lational efforts to enable the application of this knowledge 
into clinical care.
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